Strand is a privately held company that has pioneered the practice of scientific intelligence in the health sciences. Leveraging its unmatched interdisciplinary scientific expertise with its decision enabling technologies, Strand empowers biomedical and research scientists gain deep insights from raw data. Strand offers products and services in the areas of omics-based technologies, drug discovery, predictive systems modeling and knowledge management.

Seven of the top ten pharmaceutical companies, three of the top six biotechnology companies, and numerous academic institutions across the globe, are part of Strand's esteemed customer profile. Strand is a portfolio company of UTI Venture Funds, Sequoia Capital, and MediBIC group (Japan).

Strand Life Sciences (Strand) has announced a collaboration with Kidwai Memorial Institute of Oncology (ranked one among the top 5 cancer centers in the country) and Indian Institute of Science (IISc – India’s premier science research institute), to conduct an in-depth “molecular omics” study of breast cancer in the Indian population. This research program is aimed at identification and validation of molecular signatures and biomarkers for Indian breast cancer patients. Pragma front ends Strand's relationship with media around this announcement and helping Strand's value prop and positioning reach its target audience.